Juvenile Diabetes Research Foundation (JDRF): Safe and Effective Use of SGLT Inhibitors for Type 1 Diabetes - LOI

Supports research projects that will increase safe and effective use of SGLT inhibitors for T1D.
Examples of research appropriate for this RFA include but are not limited to:
*Development and testing of education/safety/monitoring tools or protocols to prevent DKA
*Physiology studies to better understand ketosis and DKA
*Development of pharmacological or other interventions to prevent DKA
*Development and/or testing of novel and user-friendly ketone monitoring technologies
*Assessment of real world efficacy and safety outcomes for SGLT inhibitors in T1D
*Data analysis to determine T1D patient characteristics (demographic, clinical, biological, behavioral, T1D management regimen, other) that predict efficacy and/or safety of SGLT inhibitors
*Additional analysis of data from pivotal phase 3 clinical studies

Funding: $400,000 for 2 years.

Overhead 10% - Please contact Research Authority if planning to submit.

http://grantcenter.jdrf.org/wp-content/uploads/2019/09/SGLTi-RFA-FINAL.pdf